The House of Representatives has passed HR 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act), as well as 2 other bills dealing with drug prices: HR 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and HR 938, the Bringing Low-cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act of 2019.
The House of Representatives has passed HR 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act), as well as 2 other bills dealing with drug prices: HR 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and HR 938, the Bringing Low-cost Options and Competition While Keeping Incentives for New Generics (BLOCKING) Act of 2019.
Whether or not the bills, which generally have bipartisan support, progress through the Senate and onto the president’s desk remains to be seen. The bills were packaged into the larger HR 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act, which includes other bills targeting the Trump administration’s actions towards the Affordable Care Act.
The Washington Post reported recently that the move is aimed at undermining any Republican messaging on healthcare, as it restores funding for Affordable Care Act marketing and outreach as well as rescinds the expansion of short-term, limited duration health plans.
The CREATES Act has enjoyed broad bipartisan support since it was first introduced. It would allow a biosimilar or generic developer to bring a civil action against an innovator drug company if the latter refuses to make available enough samples of a product for testing. A parallel piece of legislation is also before the Senate.
CREATES was the target of heavy opposition from the Pharmaceutical Research and Manufacturers of America, which says that the proposed legislation would expose brand-name drug makers to significant risk and hinder innovation. But it has been praised by the Association of Accessible Medicines (AAM), which represents generic and biosimilar drug makers.
The BLOCKING Act discourages generic drug makers from delaying the start of their 180-day exclusivity period, allowing the FDA to approve a second generic application before the start of the first applicant’s commercial marketing.
The Protecting Consumer Access to Generic Drugs Act makes future pay-for-delay settlements between brand and generic drug manufacturers illegal. One report noted that in negotiations, Democrats agreed to a Republican request to strip out a portion of the bill that would have retroactively affected enforcement to 2013.
In a statement, AAM praised Congress for passing the CREATES Act, but said that, “Unfortunately, by packaging the CREATES Act with HR 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and HR 938, the BLOCKING Act of 2019, Congress has taken one step forward and two steps back. These bills, while well intentioned, will impede generic and biosimilar drug manufacturers from bringing new, safe, and more affordable medicines to market. HR 1499 and HR 938 will raise the price of medicine.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.